Contact

Satt Lutech Satt Lutech Satt Lutech

Contactez-nous 01 78 94 68 51

Vous souhaitez exploiter le projet

1/ Vos informations personnelles

2/ Vous souhaitez en savoir plus sur nos projets ou nous faire part de vos besoins/domaines d’intérêts

Précisez le(s) projet(s) innovant(s) qui vous intéressent : *
1
1

PROPOSER SON EXPERTISE

Lorem ipsum dolor sit amet, consectetur.

1/ Vos informations personnelles

1

Nom du fichier:

Taille du fichier:

1

Nom du fichier:

Taille du fichier:

Molecular signature to detect indolent prostate cancer

Market challenges

Prostate Cancer is characterized by unregulated and uncontrolled cell growth and division. It is one of the most frequent cancer diagnosed in men in developed countries, accounting for around 8% of all new cancer cases and 15%in men.
Management of localized PC is a major clinical challenge. Indeed, the majority of prostate cancers won’t evolve and are exposed to overtreatment, on the other hand a set of prostate cancers at early stage are potentially lethal and are exposed to undertreatment.
However, the medical community still lacks efficient tools or markers to classify PC accordingly and accurately identify aggressiveness of cases.

Innovative solution

A team from Sorbonne Université has developed a method for predicting the risk of prostate cancer recurrence in a subject affectedwith prostate cancer. Indeed, they have identified a set of biomarkers which allow to robustly identify a subtype of non-evolutive cases preventing from overtreatment.

Suggested applications

• Prognosis of prostate cancer

Development status

The molecular signature was obtained from a cohort of 193 patients (130 subjects with localized PC and 63 subjects with adjacent normales prostate).

Competitive advantages

• The diagnostic enables the stratification among prostate cancer patients
• The analysis of the set of biomarkers is very robust (statistical relevance)

Ce projet vous intéresse et vous souhaitez en savoir plus